Tricida

Tricida, Inc. was founded in 2013, with its headquarters in San Francisco. It is a clinical-stage biopharmaceutical company dedicated to the discovery and clinical development of treatments for kidney diseases, metabolic disorders, and cardiovascular diseases. The company has developed a lead drug—TRC101—for the treatment of chronic kidney disease (CKD). This drug is not absorbed by the human body and can remove excess electrolytes from patients in the gastrointestinal tract, potentially helping patients avoid the suffering caused by dialysis.